Inc. (NASDAQ:INCR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On October 6, 2017, the Board of Directors of Milestone Scientific Inc. (the “Company”) appointed Michael McGeehan as a new independent director of the Company, to serve until the next annual meeting of the stockholders of the Company. The Board also appointed Mr. McGeehan to the Audit Committee, replacing Leslie Bernhard, the Company’s current Chairman of the Board, who was recently appointed as Interim Chief Executive Officer of the Company, and appointed Leonard Schiller, a current member of the Audit Committee, as Chairman of the Audit Committee.

Michael McGeehan is a business consultant with 30 years of experience in a variety of business domains, including financial services, medical and healthcare products, consumer package goods and the software technology industry. Mr. McGeehan started his career at Metaphor Computer Systems in 1988 and then went to work at Microsoft Corporation in 1991. In 1995, Mr. McGeehan left Microsoft and founded Forefront Information Strategies, an information technology consulting firm. In 2002, Mr. McGeehan returned to Microsoft where he worked until 2017, when he returned to and re-started Forefront. Mr. McGeehan is on the Board of Directors at Wand Dental Inc., a maker of a painless, anesthetic injection system for dentists. Mr. McGeehan has a Masters in Business Administration from Pace University and a Bachelors of Science in Electrical Engineering and Computer Science from Marquette University.

In addition, the Board appointed current director Edward J. Zelnick, M.D. to the Compensation Committee to replace Ms. Bernhard and appointed Mr. Schiller, a current member of the Compensation Committee, as Chairman of the Compensation Committee. The Board also appointed Mr. Schiller to the Nominating and Corporate Governance Committee.

About Inc. (NASDAQ:INCR)

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.